Alto Neuroscience (Alto Neuroscience) Buildings And Improvements : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Buildings And Improvements?

Alto Neuroscience Buildings And Improvements Historical Data

The historical data trend for Alto Neuroscience's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Buildings And Improvements Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Buildings And Improvements

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial			-	-	-	-	-

Alto Neuroscience Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024